https://www.statcounter.com/counter/counter.js
Web Analytics

ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients

Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial.

The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems of such patient population.

A previously held study, the findings of which were published in Annals of Neurology last year, demonstrated that administration of the probiotic led to changes in the composition of gut microbiota in multiple sclerosis patients apart from increasing anti-inflammatory biomarkers.

The new Visbiome clinical trial in MS patients will explore the outcomes further with an aim to determine if targeting the microbiome can offer a therapeutic strategy for multiple sclerosis patients.

Visbiome clinical trial in MS patients

Visbiome clinical trial in MS patients to be held by Columbia University Irving Medical Center and the University of Pittsburgh researchers. Photo courtesy of ExeGi Pharma.

Marc Tewey – CEO of ExeGi Pharma, commenting on the Visbiome clinical trial in MS patients, said: “We are excited about this opportunity to expand upon the available information on the effects of probiotics in multiple sclerosis patients. The probiotic formulation in Visbiome has been the subject of over 70 human clinical studies, including a preliminary study in 2018 in MS patients.

“The findings of this new study will be beneficial for the scientific community as a whole by contributing important information about the complex relationship between the microbiome and immune system.”

According to ExeGi Pharma, Visbiome is a high probiotic made up of eight strains of live, freeze-dried lactic acid bacteria.

The probiotic product is a medical food developed for the dietary management of dysbiosis related to ulcerative colitis, irritable bowel syndrome (IBS), pouchitis, and hepatic encephalopathy. ExeGi Pharma claims that Visbiome is a non-drug therapy that addresses distinct nutritional requirements, to promote microbial balance, in people with such disorders.

Rebecca Farber – Columbia University Vagelos College of Physicians and Surgeons assistant professor of neurology, and one of the lead researchers on the Visbiome clinical trial in MS patients, said: “The gut microbiome plays an important role in modulating the immune system, which is dysregulated in individuals with MS. This study will enhance our understanding about whether probiotics may be able to advantageously reshape the immune system and prevent degeneration of the nervous system.”

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *